Abstract
One of the intensively developing approaches to the treatment of oncologic diseases is directed (targeted) radionuclide therapy. Radionuclide therapy avoids the side effects associated with external beam therapy. Furthermore, it is possible to combine the processes instrumental diagnostics and radiotherapy (theranostics), which leads to personalize the treatment regimen for each individual patient. In this review, we discuss the fundamentals of targeted radionuclide therapy, including the characteristics of the radionuclides and biomolecular targeting moieties. Information on the targeted radionuclide therapy drugs for approved for clinical use is provided. Prospects and limitations of the targeted radionuclide therapy and their implementation in clinical practice are discussed.
| Translated title of the contribution | Targeted radionuclide therapy: current status and prospects |
|---|---|
| Original language | Russian |
| Pages (from-to) | 23-29 |
| Number of pages | 7 |
| Journal | Genes and Cells |
| Volume | 10 |
| Issue number | 2 |
| Publication status | Published - 1 Dec 2015 |
| Externally published | Yes |
Keywords
- oncological diseases
- radioimmunotherapy
- targeted drugs
- targeted radionuclide therapy
- tumour cells